Enzoloy-D Tablet is a combination pharmaceutical formulation containing Trypsin (48 mg), Bromelain (90 mg), Rutoside (100 mg), and Diclofenac (50 mg), designed to provide effective anti-inflammatory, analgesic, and fibrinolytic effects. Trypsin and Bromelain are proteolytic enzymes that facilitate the breakdown of proteins, aiding in the reduction of inflammation and edema by promoting the removal of necrotic tissue and enhancing tissue repair. Rutoside, a bioflavonoid, acts as a vascular protector by strengthening capillary walls, reducing capillary permeability, and exhibiting antioxidant properties, thereby minimizing bruising and swelling. Diclofenac, a nonsteroidal anti-inflammatory drug (NSAID), provides potent analgesic and anti-inflammatory effects by inhibiting cyclooxygenase enzymes, leading to decreased prostaglandin synthesis. This combination is particularly beneficial in managing acute musculoskeletal conditions such as sprains, strains, contusions, and postoperative inflammation, where both enzymatic debridement and symptomatic relief are required. Enzoloy-D should be administered under medical supervision, considering contraindications such as hypersensitivity to NSAIDs, active gastrointestinal ulcers, or bleeding disorders. The tablet is intended for short-term use to optimize recovery and improve patient comfort by addressing multiple pathophysiological pathways involved in inflammation and tissue injury.